Tatva Chintan Pharma [TATVA] vs Tanfac Industries [TANFACIND] Detailed Stock Comparison
Tatva Chintan Pharma
NSE
Loading...
Tanfac Industries
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Tatva Chintan Pharma wins in 6 metrics, Tanfac Industries wins in 14 metrics, with 0 ties. Tanfac Industries appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Tatva Chintan Pharma | Tanfac Industries | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 333.96 | 47.66 | Tanfac Industries |
| Price-to-Book Ratio | 3.21 | 14.73 | Tatva Chintan Pharma |
| Debt-to-Equity Ratio | 4.93 | 13.28 | Tatva Chintan Pharma |
| PEG Ratio | 12.21 | 0.67 | Tanfac Industries |
| EV/EBITDA | 64.22 | 35.45 | Tanfac Industries |
| Profit Margin (TTM) | 1.82% | 15.83% | Tanfac Industries |
| Operating Margin (TTM) | 7.15% | 19.10% | Tanfac Industries |
| EBITDA Margin (TTM) | 7.15% | 19.10% | Tanfac Industries |
| Return on Equity | 0.77% | 32.50% | Tanfac Industries |
| Return on Assets (TTM) | 0.68% | 20.50% | Tanfac Industries |
| Free Cash Flow (TTM) | $-516.01M | $-641.87M | Tatva Chintan Pharma |
| Dividend Yield | 0.10% | 0.34% | Tanfac Industries |
| 1-Year Return | 0.30% | 131.94% | Tanfac Industries |
| Price-to-Sales Ratio (TTM) | 6.01 | 8.25 | Tatva Chintan Pharma |
| Enterprise Value | $23.92B | $46.00B | Tanfac Industries |
| EV/Revenue Ratio | 6.07 | 8.26 | Tatva Chintan Pharma |
| Gross Profit Margin (TTM) | 50.07% | 38.17% | Tatva Chintan Pharma |
| Revenue per Share (TTM) | $168 | $558 | Tanfac Industries |
| Earnings per Share (Diluted) | $3.03 | $96.67 | Tanfac Industries |
| Beta (Stock Volatility) | 0.24 | -0.19 | Tanfac Industries |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Tatva Chintan Pharma vs Tanfac Industries Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Tatva Chintan Pharma | 2.00% | -7.42% | -3.72% | 5.45% | 43.08% | 17.75% |
| Tanfac Industries | 1.41% | -5.45% | -4.11% | 17.60% | 55.08% | 50.48% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Tatva Chintan Pharma | 0.30% | -59.83% | -55.38% | -55.38% | -55.38% | -55.38% |
| Tanfac Industries | 131.94% | 432.80% | 2,580.25% | 9,559.01% | 13,653.28% | 9,448.91% |
News Based Sentiment: Tatva Chintan Pharma vs Tanfac Industries
Tatva Chintan Pharma
News based Sentiment: MIXED
September was a month of contrasts for Tatva Chintan, with exceptionally strong Q1 FY25-26 financial results being tempered by a subsequent stock price decline and mixed analyst opinions. While the company demonstrates solid growth, investor sentiment appears cautious, creating a mixed outlook for the near term.
Tanfac Industries
News based Sentiment: MIXED
September was a month of conflicting signals for Tanfac Industries. While the company reported positive Q1 FY26 results, concerns about its valuation intensified, leading to a downgrade from StockInvest.us. This creates a mixed investment picture, requiring careful consideration of both the company's strengths and weaknesses.
Performance & Financial Health Analysis: Tatva Chintan Pharma vs Tanfac Industries
| Metric | TATVA | TANFACIND |
|---|---|---|
| Market Information | ||
| Market Cap | ₹24.80B | ₹47.48B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 50,247 | 8,318 |
| 90 Day Avg. Volume | 69,429 | 9,739 |
| Last Close | ₹1,011.90 | ₹4,607.35 |
| 52 Week Range | ₹621.00 - ₹1,232.75 | ₹2,510.00 - ₹5,064.30 |
| % from 52W High | -17.92% | -9.02% |
| All-Time High | ₹2,977.80 (Nov 01, 2021) | ₹5,064.30 (Aug 29, 2025) |
| % from All-Time High | -66.02% | -9.02% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.67% |
| Quarterly Earnings Growth | 0.28% | 0.80% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.16% |
| Operating Margin (TTM) | 0.07% | 0.19% |
| Return on Equity (TTM) | 0.01% | 0.33% |
| Debt to Equity (MRQ) | 4.93 | 13.28 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹315.61 | ₹312.76 |
| Cash per Share (MRQ) | ₹6.02 | ₹37.20 |
| Operating Cash Flow (TTM) | ₹145.88M | ₹328.42M |
| Levered Free Cash Flow (TTM) | ₹57.13M | ₹-932,025,344 |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.10% | 0.34% |
| Last 12-Month Dividend | ₹1.00 | ₹16.00 |
Valuation & Enterprise Metrics Analysis: Tatva Chintan Pharma vs Tanfac Industries
| Metric | TATVA | TANFACIND |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 333.96 | 47.66 |
| Forward P/E | 37.59 | N/A |
| PEG Ratio | 12.21 | 0.67 |
| Price to Sales (TTM) | 6.01 | 8.25 |
| Price to Book (MRQ) | 3.21 | 14.73 |
| Market Capitalization | ||
| Market Capitalization | ₹24.80B | ₹47.48B |
| Enterprise Value | ₹23.92B | ₹46.00B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 6.07 | 8.26 |
| Enterprise to EBITDA | 64.22 | 35.45 |
| Risk & Other Metrics | ||
| Beta | 0.24 | -0.19 |
| Book Value per Share (MRQ) | ₹315.61 | ₹312.76 |
Financial Statements Comparison: Tatva Chintan Pharma vs Tanfac Industries
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TATVA | TANFACIND |
|---|---|---|
| Revenue/Sales | ₹1.17B | ₹1.76B |
| Cost of Goods Sold | ₹583.46M | ₹1.09B |
| Gross Profit | ₹585.18M | ₹671.84M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹83.59M | ₹250.88M |
| EBITDA | ₹184.85M | ₹299.13M |
| Pre-Tax Income | ₹91.01M | ₹246.48M |
| Income Tax | ₹24.50M | ₹52.96M |
| Net Income (Profit) | ₹66.51M | ₹193.52M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TATVA | TANFACIND |
|---|---|---|
| Cash & Equivalents | ₹113.74M | ₹301.18M |
| Total Current Assets | ₹2.65B | ₹2.46B |
| Total Current Liabilities | ₹960.27M | ₹1.08B |
| Long-Term Debt | ₹0 | N/A |
| Total Shareholders Equity | ₹7.39B | ₹3.12B |
| Retained Earnings | ₹3.09B | ₹2.62B |
| Property, Plant & Equipment | ₹551.54M | ₹1.68B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TATVA | TANFACIND |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TATVA | TANFACIND |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 50,247 | 8,318 |
| Average Daily Volume (90 Day) | 69,429 | 9,739 |
| Shares Outstanding | 23.39M | 9.98M |
| Float Shares | 6.55M | 3.51M |
| % Held by Insiders | 0.73% | 0.75% |
| % Held by Institutions | 0.08% | 0.00% |
Dividend Analysis & Yield Comparison: Tatva Chintan Pharma vs Tanfac Industries
| Metric | TATVA | TANFACIND |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹16.00 |
| Last 12-Month Dividend Yield | 0.10% | 0.34% |
| 3-Year Avg Annual Dividend | ₹1.67 | ₹7.50 |
| 3-Year Avg Dividend Yield | 0.14% | 0.30% |
| 3-Year Total Dividends | ₹5.00 | ₹22.50 |
| Ex-Dividend Date | Sep 12, 2025 | Sep 17, 2025 |